# A Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Patients With Atopic Dermatitis

> **NCT07015762** · PHASE1 · RECRUITING · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 9 (estimated)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** IBI3002
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07015762
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-14
- **Primary completion:** 2026-05-20
- **Final completion:** 2026-05-20
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2025-08-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07015762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07015762, "A Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Patients With Atopic Dermatitis". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT07015762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*